Promedior has raised a total of $76 million from leading global healthcare venture investors since its inception in 2006. Promedior's investors include Morgenthaler Ventures, HealthCare Ventures, Polaris Partners, Forbion Capital Partners, Easton Capital, Fibrotec Ventures, Shire, and BioMed Ventures.

Morganthaler Ventures
HealthCare Ventures
Polaris Venture Partners
Forbion Capital Partners
Easton Capital
Fibrotec Ventures
Shire Pharmaceuticals
BioMed Ventures
Promedior Pipeline

Based on the broad potential of its Pentraxin-2 platform, Promedior is developing a pipeline of treatments for multiple indications. Learn More >